These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 456404)
1. Indobufen (K 3920), a new inhibitor of platelet aggregation: effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man. Tamassia V; Corvi G; Fuccella LM; Moro E; Tosolini G; Tremoli E Eur J Clin Pharmacol; 1979 Jun; 15(5):329-33. PubMed ID: 456404 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic, bioavailability and pharmacodynamic study of indobufen (K 3920), an inhibitor of platelet aggregation, after a single dose in man. Fuccella LM; Corvi G; Moro E; Pogliani E; Tamassia V; Tosolini G Eur J Clin Pharmacol; 1979 Jun; 15(5):323-7. PubMed ID: 456403 [TBL] [Abstract][Full Text] [Related]
4. Effect of age on the pharmacokinetics of indobufen. Savazzi GM; Castiglioni A; Cavatorta A; Garini G; Montanari M; Borghetti A Int J Clin Pharmacol Ther Toxicol; 1986 May; 24(5):265-9. PubMed ID: 3733275 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of platelet aggregation in man by indobufen (K 3920). Vittoria A; Laghi Pasini F; Messa GL; Di Perri T; Corvi G; Fuccella LM J Int Med Res; 1981; 9(1):12-7. PubMed ID: 7202826 [TBL] [Abstract][Full Text] [Related]
6. Different patterns of inhibition of adrenaline-induced platelet aggregation and kinetics in vivo by acetylsalicylic acid and indobufen. Fortunato JS; Pinheiro MJ; Monteiro MC; Rodrigues MA; Amaral I J Int Med Res; 1991; 19(4):305-17. PubMed ID: 1916004 [TBL] [Abstract][Full Text] [Related]
7. Comparison of aspirin and indobufen in healthy volunteers. Lee JY; Sung KC; Choi HI Platelets; 2016; 27(2):105-9. PubMed ID: 26083594 [TBL] [Abstract][Full Text] [Related]
8. In vitro and ex vivo effects of indobufen on human platelet aggregation, the release reaction and thromboxane B2 production. Cattaneo M; Bevilacqua C; Lecchi A; Mannucci PM Haemostasis; 1987; 17(5):293-300. PubMed ID: 3666587 [TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis. Yang M; Ye Z; Mei L; Ullah I; Tan C; Wang G; Gu Q; Lu Y; Abdus S; Shi L; Gong X; Bai J; Eikelboom JW; Li C Eur J Clin Pharmacol; 2021 Dec; 77(12):1815-1823. PubMed ID: 34331551 [TBL] [Abstract][Full Text] [Related]
10. Effects of ticlopidine and indobufen on platelet aggregation induced by A23187 and adrenaline in the presence of different anticoagulants. Cimminiello C; Milani M; Uberti T; Arpaia G; Bonfardeci G J Int Med Res; 1989; 17(6):514-20. PubMed ID: 2516825 [TBL] [Abstract][Full Text] [Related]
11. Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk. Mannucci L; Maderna P; Colli S; Lavezzari M; Sirtori CR; Tremoli E Thromb Res; 1987 Nov; 48(4):417-26. PubMed ID: 3445229 [TBL] [Abstract][Full Text] [Related]
12. [Activation and functions of blood platelets in patients with diabetes mellitus type 1 before and during the treatment with indobufen]. Dmoszyńska-Giannopoulou A; Sokołowska B; Ledwozyw A Pol Arch Med Wewn; 1990 Mar; 83(3):97-103. PubMed ID: 2216938 [TBL] [Abstract][Full Text] [Related]
13. Antiaggregant effect of indobufen (K3920) measured by the platelet aggregate filtration pressure test (PAFP). Visonà A; Davanzo S; Bruno R; Pagnan A J Int Med Res; 1983; 11(1):10-4. PubMed ID: 6832462 [TBL] [Abstract][Full Text] [Related]
14. [Long-term effects of indobufen on several parameters of blood platelet function in subjects at thrombotic risk]. Di Blasi S; Pintacuda S; Ferotti N; Lo Coco L; Muratore A; Russo G; Di Blasi U; D'Alessandro M; Morici G; Fornaciari M G Clin Med; 1990 Dec; 71(12):727-31. PubMed ID: 2150826 [TBL] [Abstract][Full Text] [Related]
15. Inhibitory activity of indobufen (*) on platelet aggregation in vivo. Bergamaschi M; Pierucci L; Branzoli U Pharmacol Res Commun; 1984 Oct; 16(10):979-85. PubMed ID: 6438651 [TBL] [Abstract][Full Text] [Related]
16. Specific inhibition of 40 K protein phosphorylation in platelet by a new antithrombotic agent, d-indobufen. Mamiya S; Hagiwara M; Ishikawa T; Hidaka H Thromb Res; 1989 Jun; 54(5):447-56. PubMed ID: 2505401 [TBL] [Abstract][Full Text] [Related]
17. [Evaluation of morning platelet aggregation in patients with ischemic cardiopathy after evening administration of indobufen]. Craveri A; Lanfredini M; Citella C; Braconaro F; Colombo L Minerva Cardioangiol; 1988 Sep; 36(9):411-8. PubMed ID: 3226570 [No Abstract] [Full Text] [Related]
18. The d-enantiomer form of indobufen totally accounts for the anti-cyclooxygenase and antiplatelet activity ex vivo and for the increase in bleeding time by indobufen in man. De Caterina R; Sicari R; Yan A; Bernini W; Giannessi D; Lazzerini G; Efthymiopoulos C; Strolin-Benedetti M Thromb Haemost; 1992 Feb; 67(2):258-63. PubMed ID: 1621247 [TBL] [Abstract][Full Text] [Related]
19. Indobufen: an updated review of its use in the management of atherothrombosis. Bhana N; McClellan KJ Drugs Aging; 2001; 18(5):369-88. PubMed ID: 11392445 [TBL] [Abstract][Full Text] [Related]
20. The dispositional enantioselectivity of indobufen in man. Strolm Benedetti M; Frigerio E; Tamassia V; Noseda G; Caldwell J Biochem Pharmacol; 1992 May; 43(9):2032-4. PubMed ID: 1596290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]